Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: Celgene
Yahoo Beta:0.45

Company Description:  Celgene discovers, develops, produces, and sells drugs, primarily for treating forms of blood cancer and other illnesses. Its primary markets are the US and Europe, but the company sells its drugs internationally.

Purchase Date:24 Feb 2010 Sale Date:20 Apr 2011
Purchase Price:$59.20 Sale Price:$56.51
  --Split Adjusted:$59.20  --Split Adjusted:$56.51
Shares Purchased:50 Shares Sold:50
  --Split Adjusted:50  --Split Adjusted:50
Transaction Fee:$72.06 Transaction Fee:$80.41
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$60.04 High$0.00
Date19 Feb 2010 Date01 Jan 1996
Low$50.21 Low$0.00
Date02 Nov 2009 Date01 Jan 1996
S&P (Purchase Date):$1,103.46 S&P (Sale Date):$1,328.28

Timing:  We bought near the six month high.
Reason:  Revlamid, Celgene's premier drug, is currently approved for second line treatment. It is under FDA approval for first line treatment. Data to date indicate it has much higher efficacy than current first line treatments. If the drug is approved as a first line treatment, we expect sales to rise considerably. The company also has a reasonable pipeline.

Reason:  We initially bought Celgene on the premise that Revlamid would become a first line treatment. Recently, there have been studies suggesting that Revlamid may promote secondary tumors in a fraction of patients. Therefore, we do not expect our cash flow projections will be realized.

S&P Gain: 20.37 % Annualized Gain: 19%
Stock Gain: -4.54 % Annualized Gain: -4.27%

Net Holding Return ($): $-286.97
Net Holding Return (%): -9.46 %